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Intensive Treatment With Ivermectin and Iota-Carrageenan as
Pre-exposure Prophylaxis for COVID-19 in Health Care
Workers From Tucuman, Argentina
To the Editor:
After COVID-19 emerged, a multitude of both novel
and repurposed therapeutic agents were used empiri-
cally and studied in controlled clinical trials.1–3 Iver-
mectin is a broad spectrum antiparasitic agent that has
shown to have antiviral activity against a wide range
of viruses.4,5 On March 31, the World Health Organi-
zation (WHO) stated that evidence about ivermectin
use for COVID-19 treatment is not conclusive. How-
ever, it encouraged its utilization in controlled clinical
trials. At June 2021, there were 65 studies registered at
https://www.ClinicalTrials.gov and 45 studies listed
at https://ClinicalTrials.gov/ct2/who_table about the
safety and effectiveness of ivermectin in subjects with
COVID-19, of which 16 studies have been completed
(for COVID-19 treatment). Most of these studies on
ivermectin repositioning came from developing coun-
tries like ours, Argentina, with limited access to vac-
cines. These emergent economies have the need to find
supportive therapies that are synergistic or alternatives
to contain the spread of the disease and deter the
health systems’ collapse.
Kory’s meta-analysis (2021) reported that ivermectin
has antiviral and anti-inflammatory mechanisms with
statistically significant positive outcome.6 However,
most of these studies were not published in peer-
reviewed journals; nevertheless, several expert groups
including the WHO have undertaken a global effort to
contact all active clinical trials to rapidly gather the
data needed to perform a systematic review and
meta-analyses. In Kory’s publication,6 ivermectin
showed ability to prevent transmission and improve-
ment in the treatment in both observational9,10 and
randomized trials.7,8,11,12,13 Our work was included
in this systematic review. This letter to the editor aims
to provide more details of our findings, presenting
experimental evidence for the prophylactic use of
ivermectin associated with iota-carrageenan in health
workers.12
We conducted a randomized controlled 1-1 clinical trial
(registry number NCT04701710 www.ClinicalTrial.gov)
in 234 adults. The subjects were divided into the experi-
mental group (EG), n 5 117, median age5 40 years [in-
terquartile range (IQR), 32–46], and 65 F (55.56%) and the
control group (CG) n5 117, 37 years (IQR, 33–44), and 69
F (58.97%). All subjects completed the study; 134 were
female (57.3%) and 100 were men (42.7%), and 77.4%
were health care workers (Table 1). The experimental
group received ivermectin orally 2 tablets of 6 mg every
7 days and iota-carrageenan 6 sprays per day for 4 weeks.
All participants were evaluated by physical examination
and COVID-19 diagnosedwith negative reverse transcrip-
tion polymerase chain reaction at the protocol baseline.
We calculated odds ratio (OR) and created a logistic
regression using comorbidity, sex, age, and job designa-
tion as covariables. A P value , 0.05 was considered
significant.
The number of subjects who were diagnosed with
COVID-19 in the EG was lower than subjects in the
CG (P value 5 0.0001), Figure 1A. Overall, 19 patients
had mild symptoms, 4 were in the EG whereas 15 were
in the CG (P value5 0.001), Figure 1B. The probability of
becoming ill with COVID-19 was significantly lower in
the EG [OR 0.13, 95% confidence interval (CI) 0.03–0.40;
P value 5 0.0001]. We also found that increasing age
decreases the risk of contagion (OR 5 0.93, 95% CI
0.88–0.98, P value 5 0.02). The probability of contracting
COVID-19 was dependent on the subject’s pre-existing
comorbidity (OR 3.45, 95% CI 1.55–7.67, P value 5
0.002). The other variables (sex and job designation)
did not have influence on COVID-19 infection.
Health personnel are one of the most exposed groups to
COVID-19 because of their steady contact with infected
patients. In this study, treatment with IVER/IOTACRC
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for pre-exposure prophylaxis to COVID-19 has shown
a protective effect over the control group. People infected
with COVID-19 at the end of the follow-up was signifi-
cantly higher in the CG compared with the EG (Figure 1B).
Our findings are supported by several recent preven-
tion trials such as Alam et al10 (also cited by Kory’s meta-
analysis), who conducted an observational prophylactic
study in 118 health care workers and found significant
less contagious infection in subjects who received iver-
mectin.6,10 Our findings, similarly to Carvallo et al and
Abd-Elsalam et al, confirm the hypothesis that IVER/
IOTACRC decreases the possibility of infection with
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) and possibly acts synergistically.9,14,15 We hypoth-
esize that a double viral barrier is formed, enhancing its
action in the following ways: (1) The first barrier for viral
protection would be at the entry of the virus into the nasal
cavity where the carrageenan would behave as a muco-
lytic agent in the barrier of sulfated polysaccharides with
negative charge9; (2) ivermectin decreases the viral load
based on its systemic cellular action.5,16 Ivermectin has
shown viral clearance in other clinical trials which
Table 1. Demographic profile.
Variables Experimental Group (n5 117) Control Group (n5 117)
Demographic profile
Median age (in yr) 40 37
IQR IQR25: 32; IQR75: 46 IQR25: 33; IQR75: 44
Sex, no. (%)
Female 65 (55.56%) 69 (58.97%)
Male 52 (44.44%) 48 (41.03%)
Comorbidities, no. (%)
Hypertension 13 (11.11%) 8 (7.55%)
Diabetes 10 (8.55%) 7 (6.60%)
Obesity 10 (8.55%) 18 (16.98%)
.60 yrs 5 (4.27%) 5 (4.27%)
Chronic kidney disease 3 (1.36%) 2 (1.89%)
Designation
Health care personnel 99 (84.62%) 82 (70.09%)
Not an health care personnel 18 (15.38%) 35 (29.91%)
FIGURE 1. COVID-19 case in the EG versus the CG. (A) Number of COVID-19 cases and healthy cases in the experi-
mental and control group (n 5 234). (B) Clinical state of the COVID-19 cases in the experimental and control group (n 5
234). The most frequent symptoms were fever experienced by 21 patients (17%) in the CG versus 1 (0.9%) in the EG (21),
P , 0$0001. Nineteen patients (16%) in the CG experienced taste and/or smell disturbances and 0 (0%) in the EG, P ,
0$0001. Furthermore, 19 patients (16%) experienced headache in the CG versus 1 (0$9%) in the EG, P , 0.0001. A higher
frequency of polyarthralgia, diarrhea, abdominal pain, and low oxygen saturation was also reported in the control
group. Acute lower respiratory infection symptoms and signs were reported in 1 patients in the control group.
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evaluate its use to treat COVID-19. Kolewieski et al found
that a 5-day intensive treatment of ivermectin resulted in
earlier clearance of the virus compared with the control
group.8
Ivermectin can prevent the entry into the cell nucleus
of the viral RNA by blocking importin alpha/beta,
thereby preventing replication because SARS-CoV-2
does not have the nuclear mechanisms and enzymatic
actions for the transcription of new viral replicates.4
Our study is supported by findings which demon-
strated the effect of ivermectin as a drug for inhibiting
viral replication in vitro and places the drug as a new
therapeutic candidate against SARS-CoV-2.16,17 In
a meta-analysis published in June 2021, Bryant et al
after analyzing different clinical trials showed that iver-
mectin may have beneficial effects in both prophylaxis
and treatment of Covid-19.18
Our study shows agreement with other research
groups regarding positive findings in the use of iver-
mectin for the treatment of COVID-19 that deserves
further studies about repurposing ivermectin.
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Immune-Mediated Thrombocytopenia Associated With
Ad26.COV2.S (Janssen; Johnson & Johnson) Vaccine
To the Editor:
Immune thrombocytopenia (ITP) is an acquired coa-
gulopathy caused by antibody-mediated platelet de-
struction. Patients may be asymptomatic or may
present with mucocutaneous to life-threatening bleed-
ing.1 Vaccines such as influenza, MMR, hepatitis B,
and diphtheria-tetanus-pertussis have been reported
to cause ITP.2 Approximately 40 cases of ITP were
reported to the Vaccine Adverse Event Reporting Sys-
tem after receiving the Pfizer and Moderna COVID-19
vaccines by the end of January 2021.3 It is unknown
whether these cases include those with pre-existing
thrombocytopenia. Here, we present a case report of
an elderly woman presenting with life-threatening
thrombocytopenia after receiving the Ad26.COV2.S
(Janssen; Johnson & Johnson, New Brunswick, NJ) vac-
cine. To the best of our knowledge, this is the first
publication of isolated severe thrombocytopenia in a
patient with no pre-existing risk factors after receiving
the Ad26.COV2.S vaccine.
A 63-year-old woman with a medical history of cer-
vical cancer status after total hysterectomy, presented
to the hospital with complaints of bleeding from her
gums for the past 3 days. Seventeen days before pre-
sentation, the patient had received the Ad26.COV2.S
(Janssen; Johnson & Johnson) vaccine. She did not
experience any major side effects after her vaccination
except for muscle soreness at the administration site.
She did not have fever, chills, shortness of breath, or
recent infections. A week later, she went for a routine
dental checkup which was unremarkable. She started
experiencing bleeding in her gums 3 days before pre-
sentation. She later had sudden onset nose bleeds which
prompted her to go to the emergency department.
On presentation to the emergency department, the
patient was hemodynamically stable and afebrile. Her
bleeding had resolved. Complete blood count showed
hemoglobin 12.2 g/dL, hematocrit 36.3%, white blood
cell count 10.9 3 103 cells/uL, and significant severe
thrombocytopenia 2 3 109/L. Her international nor-
malized ratio was 1.02, with a prothrombin time of
13.5 seconds and a partial thromboplastin time of
27.0 seconds. Hemolytic workup was completed with
lactate dehydrogenase 150 U/L, haptoglobin 192
mg/dL, and D-dimer 0.76.
On admission, she received 2 units of platelets. She
was also given a one-time dose of prednisone 60 mg
orally. Her repeat platelet count posttransfusion im-
proved to 14 3 109/L. Hematology was consulted
and recommended starting the patient on immune
globulin (human) infusion intravenously and dexa-
methasone 20 mg daily.
Throughout admission, the patient’s platelet count
steadily increased. She did not have further bleeding
episodes and did not require additional platelet trans-
fusions. Testing for HIV and hepatitis B and C was
negative. Heparin-induced platelet IgG antibody was
negative. Imaging including ultrasound Doppler of the
abdomen/pelvis, ultrasound Doppler of upper and
lower extremities, magnetic resonance venogram of
the head, and computed tomography angiography of
the thorax showed no evidence of thrombosis. The
patient remained hemodynamically stable throughout
admission with no signs of active bleeding. She was
ultimately deemed stable for discharge 5 days after
admission, with a platelet count of 252 3 109/L.
Immune thrombocytopenia purpura (ITP) is a diag-
nosis of exclusion characterized by a decrease in plate-
let count and prolonged bleeding time secondary to
impaired platelet production or destruction of circulat-
ing platelets. Patients are commonly asymptomatic;
however, based on the severity of thrombocytopenia,
clinical features include easy bruising, petechiae,
bleeding gums, hematuria, or melena. ITP is often trig-
gered idiopathically; however, other triggers include
previous viral or bacterial infections, lymphoma or
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